Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

Rhea-AI Summary

Crinetics Pharmaceuticals (Nasdaq: CRNX) will host a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide a PALSONIFY (paltusotine) commercialization update and to disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia (CAH).

The event includes prepared remarks followed by a live Q&A. A live audio-only webcast will be available and an archived webcast will be posted on the company's Events & Presentations page at www.crinetics.com/events. Dial-in numbers: 1-833-470-1428 (U.S.) or 1-646-844-6383 (international); Access Code: 640078.

Argus Jan 5 session

+3.10% close to close Open Argus

Details

News Market Reaction – CRNX

In the Jan 5 session, CRNX gained 3.10%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets expectations for a business update on PALSONIFY commercialization alongside t...

Analysis

This announcement sets expectations for a business update on PALSONIFY commercialization alongside topline results from the fourth cohort of a Phase 2 atumelnant trial in congenital adrenal hyperplasia. It follows recent milestones across paltusotine, atumelnant, and CRN09682. Key elements to watch include biomarker and symptom data continuity with prior Phase 2 atumelnant results, any commentary on next development steps, and how management frames the broader pipeline strategy during the January 5, 2026 call.

Key Figures

Conference date: January 5, 2026 Conference time: 8:30 a.m. ET Access code: 640078

Conference date

January 5, 2026

Scheduled business update and topline Phase 2 cohort results call

Conference time

8:30 a.m. ET

Start time for conference call and webcast

Access code

640078

Dial-in access code for live conference call

Historical Context

5 past events · Latest: Dec 18

5 events

1. Dec 18

   Conference participation

   24h Move

   +6.4%

   Announcement of J.P. Morgan Healthcare Conference presentation and webcast access.

2. Dec 11

   Phase 3 initiation

   24h Move

   +2.4%

   First patient dosed in Phase 3 CALM-CAH trial of atumelnant in adults.

3. Dec 10

   Equity inducement grants

   24h Move

   +2.6%

   Inducement stock options and RSUs granted to new non-executive employees.

4. Dec 03

   Early-stage trial start

   24h Move

   +4.4%

   First patient dosed in Phase 1/2 BRAVESST2 trial of CRN09682 in SST2+ tumors.

5. Nov 20

   Phase 3 enrollment

   24h Move

   +2.1%

   First patient randomized in pivotal Phase 3 CAREFNDR trial of paltusotine.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

congenital adrenal hyperplasia

1 terms

congenital adrenal hyperplasia medical

"Phase 2 trial of atumelnant in congenital adrenal hyperplasia."

Congenital adrenal hyperplasia is a group of inherited disorders in which the adrenal glands lack an enzyme needed to make certain hormones, causing a chronic imbalance of cortisol, aldosterone and/or sex hormones. Think of it as a factory assembly line missing a key part, so the body overproduces some products and underproduces others, requiring lifelong monitoring or hormone treatment. For investors, it matters because diagnosis, ongoing therapy, newborn screening and potential new drugs or gene therapies can drive medical spending, regulatory approvals and market opportunity in endocrinology and rare disease care.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, Jan. 04, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that the company will host a conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET to provide an update on PALSONIFY™ (paltusotine) commercialization and disclose topline results from the fourth cohort of the Phase 2 trial of atumelnant in congenital adrenal hyperplasia.

Conference Call and Webcast Details
Management will hold a live conference call and webcast on Monday, January 5, 2026 at 8:30 a.m. ET. A live question-and-answer session will follow the prepared remarks. To access the live audio-only webcast, click here. The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics’ website at www.crinetics.com/events. To participate, please dial 1-833-470-1428 (domestic) or 1-646-844-6383 (international) and refer to Access Code 640078.

ABOUT CRINETICS PHARMACEUTICALS
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases and endocrine-related tumors through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with a core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.

Crinetics’ lead product, PALSONIFY™ (paltusotine), is the first once-daily, oral treatment approved by the U.S. FDA for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option. Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics’ deep pipeline of 10+ disclosed programs includes late-stage investigational candidate atumelnant, which is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, and CRN09682, a nonpeptide drug conjugate candidate that is being developed to treat SST2 expressing neuroendocrine tumors and other SST2 expressing solid tumors. Additional discovery programs address a variety of endocrine conditions such as neuroendocrine tumors, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or thyroid eye disease), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications.

Investors:
Gayathri Diwakar
Head of Investor Relations
gdiwakar@crinetics.com
(858) 345-6340

Media:
Natalie Badillo
Head of Corporate Communications
nbadillo@crinetics.com
(858) 345-6075

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is the Crinetics (CRNX) webcast for the PALSONIFY update and atumelnant Phase 2 cohort 4 topline results?

The webcast is scheduled for January 5, 2026 at 8:30 a.m. ET.

How can investors access the Crinetics (CRNX) live audio-only webcast on January 5, 2026?

Access the live audio-only webcast via the company's site or dial 1-833-470-1428 (U.S.) or 1-646-844-6383 (international) with Access Code 640078.

Will Crinetics (CRNX) post a replay of the PALSONIFY and atumelnant presentation?

Yes, an archived webcast will be available on the Events & Presentations page at www.crinetics.com/events.

What topics will Crinetics (CRNX) address during the January 5, 2026 call?

Management will provide a PALSONIFY commercialization update and disclose topline results from the fourth cohort of the Phase 2 atumelnant trial in CAH.

Will there be a Q&A during the Crinetics (CRNX) January 5, 2026 event?

Yes, a live question-and-answer session will follow the prepared remarks.